A5005437791- Mechanical Circulatory Support Devices
- Cardiac Structural Anomalies and Repair
- Cardiac Arrest and Resuscitation
- Transplantation: Methods and Outcomes
- Cardiac Valve Diseases and Treatments
- Cardiac Ischemia and Reperfusion
- Aortic Disease and Treatment Approaches
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- Infective Endocarditis Diagnosis and Management
- Cerebrovascular and Carotid Artery Diseases
- Cardiac pacing and defibrillation studies
- Congenital Heart Disease Studies
- Long-Term Effects of COVID-19
- Cardiovascular Health and Disease Prevention
- Infectious Aortic and Vascular Conditions
- Acute Ischemic Stroke Management
- Cardiac and Coronary Surgery Techniques
- Organ Transplantation Techniques and Outcomes
- Cardiac, Anesthesia and Surgical Outcomes
- Pediatric Hepatobiliary Diseases and Treatments
- Cardiovascular and Diving-Related Complications
- Organ and Tissue Transplantation Research
- Cardiac Imaging and Diagnostics
- Intracranial Aneurysms: Treatment and Complications
Ochsner Medical Center
2014-2024
The University of Queensland
2019-2020
University of New Orleans
2016
Cleveland Clinic
2004
University of Virginia
1997-2001
Pennington Biomedical Research Center
2001
Background Few data exist on resource utilization with pediatric ventricular assist devices ( VAD s). We tested the hypothesis that device type and adverse events are associated increased in patients supported s. Methods Results The Pediatric Interagency Registry for Mechanically Assisted Circulatory Support, a national registry of s <19 years old, Health Information System, an administrative database, were merged. Univariate analysis was performed assessing association all factors total...
Aim This trial compared the hemostatic performance of a novel combination powder (CP) to control matrix (HM) in cardiothoracic operations. Methods Patients meeting eligibility criteria were enrolled after providing informed consent. Subjects randomized intraoperatively receive CP (HEMOBLAST Bellows; Biom'up, France) or HM (FLOSEAL Hemostatic Matrix; Baxter Healthcare Corporation, Hayward, CA). Bleeding was assessed using clinically validated, quantitative bleeding severity scale. The primary...
Background The European CE Mark approval study and the MOMENTUM 3 trial demonstrated safety a reduction in hemocompatibility-related adverse events with use of HeartMate (HM3) device. This single-center investigated real-world experience HM3 patients since FDA approval. Methods retrospective, observational included implanted LVAD as primary implant between October 2017 March 2020. Patients were divided into group postapproval group. endpoint was survival at 6 months. Secondary endpoints...